1	
2	
3	
4	
5	
6	
7	A comparison of the EQ-5D-5L and the SF-6Dv2 among patients with
8	hypertrophic obstructive cardiomyopathy
9	
10	Short title: EQ-5D-5L and the SF-6Dv2 in hypertrophic obstructive cardiomyopathy
11	
12	
13	Xiaoyu Wang ¹ , Haiqiang Sang ¹ *, Rui Meng ² , Xin Su ¹ , Peng Liu ¹
14	
15	¹ Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou
16	University, Zhengzhou University, Zhengzhou, Henan 450052, China
17	² School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing,
18	Jiangsu 210009, China
19	
20	
21	
22	
23	
24	*Corresponding author
25	Email: fccsanghoazzu edu ch (HS) not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

Background: Hypertrophic obstructive cardiomyopathy (HOCM) is a serious and 27 complex chronic disease severely affecting patients' daily lives and health-related quality of 28 life (HRQoL). The psychometric performance of generic preference-based instruments has 29 not been compared in Chinese patients with HOCM. We aimed to identify an applicable 30 vehicle to determine HRQoL and explore the psychometric properties of SF-6Dv2 and EQ-31 5D-5L in adults with HOCM. The interchangeability of the tools in cost-utility analysis was 32 also investigated. Methods: We collected data from 131 patients with HOCM from the First 33 Affiliated Hospital of Zhengzhou University, China. Assessments were performed on the day 34 35 of admission and three and six months after discharge using SF-6Dv2 and EQ-5D-5L. The responses were converted to utility values using the corresponding Chinese value sets. The 36 tool distributions were explored, and the floor and ceiling effects were analyzed. The 37 38 agreement was assessed using intra-class correlation coefficients (ICCs) and Bland-Altman plots. Convergent validity was tested using Spearman's rank correlation coefficient. Known 39 group validity was measured across various clinical and sociodemographic indicators using 40 relative efficiency (RE) statistics. Results: The mean utility scores for SF-6Dv2 and EQ-5D-41 5L at baseline and 6-month follow-up were 0.61, 0.62, 0.736, and 0.797, respectively. The 42 43 EQ-5D-5L and SF-6Dv2 distribution scores showed no normality. EQ-5D-5L was more sensitive to changes over time and showed a moderate to good correlation with the SF-6Dv2 44 (ICC: 0.598-0.862). The instruments' agreement and convergent validity worsened in 45 46 patients with a higher New York Heart Association (NYHA) cardiac function classification and lower general health status. SF-6Dv2 showed higher relative efficiency statistics and a 47 greater ability to distinguish external health status. Conclusions: The measured results can be 48 49 used for future cost-utility analyses. SF-6Dv2 and EQ-5D-5L presented different results and

should not be used interchangeably. SF-6Dv2 is optimal for detecting differences between
subgroups with various health states.

53 Keywords: SF-6Dv2, EQ-5D-5L, HOCM, Health-related quality of life

- 54
- 55

56 Introduction

Hypertrophic cardiomyopathy (HCM), distinguished by left ventricular myocardial 57 hypertrophy, is a class of cardiac disorders caused by genetic factors. It often has an 58 59 autosomal inheritance pattern due to variants in the genes encoding myosin (or myosinassociated genes) or may have an unknown genetic etiology [1]. The main feature of 60 hypertrophic obstructive cardiomyopathy (HOCM) is a left ventricular outflow tract pressure 61 62 difference of at least 30 mmHg at rest or with provocation. It accounts for approximately 70% of all HCM patients [2]. Currently, the prevalence of HCM in China is 0.076%, and the 63 mortality rate of HCM patients is as high as 3.38% [3]. HOCM is the main cause of sudden 64 cardiac death in adolescents and athletes and is closely related to heart failure and stroke in 65 older patients [4,5]. Typical symptoms include exertional dyspnea and weakness, chest pain, 66 67 and palpitations, which tremendously impact patients' physical health and health-related 68 quality of life (HRQoL) [6]. Parallel to this, HOCM is closely related to considerable expenditures on healthcare and imposes an enormous financial burden on global health 69 70 budgets [7].

In order to provide evidence support for decision-makers to allocate limited resources
among competing healthcare programs appropriately, cost-utility analysis (CUA) is
incrementally being used. Quality-adjusted life years (QALYs) are health outcome indicators
in CUA, which combines years of survival with utility values [8]. Utility scores are usually

expressed as a value from 0 to 1, where 1 represents perfect health and 0 represents death;
they can also be negative, reflecting a disease situation worse than death. A series of
universal health scales (multi-attribute utility instruments [MAUIs]) have been developed
internationally to measure health utility values. Among the multitude of generic preferencebased scales, the EuroQoL Five-Dimension (EQ-5D) from the European Society of Quality
of Life [EuroQoL Group] along with the Short Form Six-Dimension (SF-6D) obtained based
on the Short Form 36-item [SF-36] are among the most popular [9].

EQ-5D, developed by the EuroQol Group, is the most commonly used MAUIs 82 83 worldwide. Compared to the original version of EQ-5D-3L, which contains only three response levels for each dimension, EO-5D-5L offers five levels per dimension and lower 84 ceiling effects when conducting a survey among the population [10]. The SF-6D scale is 85 second only to the EQ-5D. Moreover, because the SF-6D scale dimension level setting is 86 87 more abundant and sensitive, it is more suitable for chronic diseases where the clinical symptoms are not obvious. Compared with SF-6D, SF-6Dv2 has a much broader scoring 88 89 range and addresses the problem of descriptive systems [11]. Differences in the structure and valuation of different instruments may give rise to various estimates of the identical "health 90 state" for the same individual, which results in discrepancies in utility and healthcare-related 91 decision-making. Therefore, it is crucial to measure the utility of HOCM patients using these 92 93 two well-known instruments and to compare the psychometric properties of measurements 94 and interchangeability.

Comparisons of the properties of SF-6D and EQ-5D measurements have already been
validated for several diseases, including depressive symptoms and fibromyalgia [12,13].
However, no studies have compared health utility values based on Chinese HOCM patients
using EQ-5D-5L and SF-6Dv2. Therefore, we aimed to estimate the utility of Chinese
patients with HOCM using EQ-5D-5L and SF-6Dv2. Furthermore, we evaluated whether

EQ-5D-5L and SF-6Dv2 revealed similar empirical estimates of health-related utility and
interchangeability in patients with HOCM.

102

103 Material and methods

104 EQ-5D-5L

The EQ-5D-5L consists of two parts: a questionnaire section and the EuroOoL-visual 105 analog scale (EQ-VAS). The questionnaire contained five dimensions, each with five severity 106 107 108 5×5) different health states described by the EQ-5D-5L questionnaire can be calculated, of which 11111 are the best health states (perfectly healthy) and 55555 are the worst state of 109 health. The EO-5D-5L utility value integral system converts a patient's health status into 110 health utility value. A Time-trade off (TTO) approach was employed to develop Chinese EQ-111 5D-5L utility values ranging from -0.391(55555) to 1(11111). Furthermore, the EO-VAS 112 indicates the patient's subjective rating of self-reported health state on the day being 113 interviewed, with a vertical length of 20 cm, starting at 100 (the best health imaginable) and 114 ending at 0 (the worst health imaginable) [15]. The value of the EQ-VAS was converted to 0-115 116 1 to facilitate comparison.

117

118 SF-6Dv2

The SF-6Dv2 serves a broader range of dimensions than the EQ-5D-5L, of which only ten items in the SF-36 have been reclassified into six items, each dimension corresponding to one item [16]. All the dimensions except pain domains (six levels) had five levels, yielding a total of 18,750 (= $5 \times 5 \times 5 \times 6 \times 5 \times 5 \times 5$) health conditions [17]. We use

the set of Chinese tariff values developed for SF-6Dv2 by the TTO method, which has a
range of values from -0.277 (555,655) to 1 (111,111).

125

126 Sampling and data collection

Participants were patients with HOCM who were hospitalized at the First Affiliated
Hospital of Zhengzhou University between 1 June 2021 and 31 October 2022. Patient
demographic characteristics and disease-related data, including age, sex, work and marital
status, educational background, body mass index (BMI), and left ventricular ejection fraction
(LVEF), were completed by the patient or extracted from the inpatient electronic medical
records.

The inclusion criteria were supposed to be in accordance with the following: 1) 133 consistent with the diagnosis of hypertrophic obstructive cardiomyopathy, and 2) the 134 completed scale contained no missing data. Patients were excluded if they 1) were under 18 135 years old, 2) refused to sign the informed consent form, or 3) had other serious illnesses or 136 psychological disorders that prevented them from understanding the contents of the 137 138 questionnaire. Eligible respondents were interviewed face-to-face on the day of admission by a research assistant who underwent a 1-day uniform professional training before the study 139 started. After filling in the questionnaire, a second research assistant verified that the 140 141 questionnaire was complete and that no items were missing. Following discharge, the patient was contacted by phone three and six months later. Upon completion of the questionnaire, the 142 patients uploaded and returned the results. 143

The study protocol was approved by the University of Zhengzhou Ethics Committee (registration number 2021-KY-0943-002), and all participants provided written informed consent before participating in the research. This study adhered to the tenets of the 1975 Declaration of Helsinki (Tokyo revision, 2004).

148

149 Statistics analysis

The baseline demographic statistics described continuous and categorical variables 150 using mean, standard deviation, and frequency, respectively. Overall quality of life (OOL) 151 indices were calculated and compared for the SF-6Dv2 and EQ-5D-5L questionnaires at three 152 time points: on the day of admission and three and six months after discharge. A histogram 153 represented the distributions of the two instruments. Normality tests were conducted using 154 the skewness and kurtosis values. Because of the highly skewed distribution of the index 155 scores, the Wilcoxon signed-rank test for differences between the index scores of the two 156 measurements was used. In contrast, the Kruskal-Wallis test was used for comparisons 157 between the index scores of the participants' characteristic groups. One-way ANOVA was 158 applied to measure changes in New York Heart Association (NYHA) cardiac function classes 159 during follow-up. Ceiling and floor effects were measured by computing the percentage of 160 respondents who received the highest or lowest scores in each field. The minimally important 161 difference (MID) is often applied to explain patient-approved minimum clinical effectiveness 162 163 questionnaire score changes reflecting HROoL. The treatment is clinically significant when the score change reaches the MID threshold. In a previous study, the average MID values of 164 the SF-6Dv2 and EQ-5D-5L were 0.041 and 0.074, respectively [18]. Intraclass correlation 165 166 coefficients (ICCs) were calculated for the SF-6Dv2 and EQ-5D-5L instruments to assess agreement, which was reported as a two-way random and absolute agreement with a single 167 metric model: ICC lies within 0.5-0.75 for moderate, 0.75-0.9 for good and more than 0.9 for 168 excellent. Bland–Altman plots were used to explore the degree of consistency between the 169 two utility scores [19]. Convergent validity is the degree to which the results correlate when 170 171 different measures are utilized to measure similar characteristics, such as anxiety/depression on the EQ-5D-5L and mental health on the SF-6Dv2. Convergent validity was evaluated by 172

173	calculating Spearman's correlation (ρ) coefficient between the domains of the two
174	instruments. The strength of the Spearman correlation was rated as weak for less than 0.3,
175	strong for more than 0.5, and moderate for in-between [20]. Known-group validity refers to
176	the ability of two instruments to distinguish between each respondent's characteristic group
177	by calculating the average utility value for each measure and comparing them [21]. We
178	examined how well SF-6Dv2 and EQ-5D-5L detected differences in the indices of external
179	health based on the relative efficiency (RE) statistic. The RE is defined as the ratio of the
180	square of the t-statistic of the comparison tool to the reference tool [22]. A value > 1.0
181	represents, when determining differences in health-related external indicators, EQ-5D-5L
182	performs better than SF-6Dv2, while a value < 1.0 illustrates that the EQ-5D-5L performs
183	less efficiently than SF-6Dv2.
184	Statistical analyses were performed using the SPSS, IBM Statistics software, version
185	22.0. In all statistical tests, p-values less than 0.01 were assumed to be statistically

186 significant.

187

188 **Results**

189 Characteristics of the study sample

Four of the 135 participants died during the follow-up period. As their questionnaires were incomplete, they were excluded from the sample. Consequently, 131 patients with HOCM were included in this study. Participants' sociodemographic and clinical characteristics at baseline are displayed in Tables 1 and 2, who were 53.4 years old, and most patients with HOCM were male, accounting for 55.7%, and 91.6% of patients were married. The mean body mass index (BMI) was 25.8 kg/m². NYHA functional class III was present in 53.4% of the patients, and the LVEF ranged from 29% to 79%, with an average of 64.4%.

- 197 We observed statistically significant differences in the NYHA cardiac function classification
- on the day of admission and at three and six months after discharge (p<0.01).
- 199

200 Table 1. Baseline characteristics

Characteristics	Total (n=131)
Age, mean (SD)	53.4 (12.1)
BMI, mean (SD)	25.8 (3.2)
EF%, mean (SD)	64.4(5.66)
EQ-5D-5L utility, mean (SD)	0.62(0.28)
SF-6Dv2 utility, mean (SD)	0.61(0.19)
EQ-VAS score, mean (SD)	0.62(0.18)

- 201 SD: Standard deviation BMI: Body Mass Index; EF: Ejection Fraction; EQ-5D-5L: 5-level
- 202 EuroQol 5-dimension; SF-6Dv2: Short Form Six-Dimension (version 2); EQ-VAS: EuroQol-
- 203 Visual Analog Scale (EQ-VAS)
- 204

205 Table 2. Known-groups validity of SF-6Dv2 and EQ-5D-5L

	Ratio%	EQ-5	5D-5L	р	SF-6	Dv2	р	RE*
Gender		Mean	SD	0.88	Mean	SD	0.10	0.01
Female	44.3	0.623	0.277		0.583	0.206		
Male	55.7	0.615	0.290		0.639	0.166		
Annual				< 0.01			< 0.0	0.77
household							1	
income								
<5K	24.4	0.450	0.299		0.490	0.178		
5K-1W	10.7	0.706	0.251		0.569	0.188		

medRxiv preprint doi: htt preprint (which was no	ps://doi.org/10.1101/2 st certified by peer re It is made	2023.10.25.2 2view) is the e available un	3297528; thi author/funde perpetuity nder a CC-B	s version po er, who has y. Y 4.0 Intern	osted Octobe granted mec ational licens	r 25, 2023. IRxiv a licen se .	The copyri ise to displ	ight holder for this ay the preprint in
1W-5W	25.2	0.674	0.282		0.652	0.153		
5W-10W	19.8	0.661	0.253		0.679	0.178		
10W-20W	9.9	0.752	0.189		0.716	0.210		
>20W	9.9	0.579	0.266		0.641	0.118		
Employment				0.10			<0.0	0.34
status							1	
Employed	32.8	0.690	0.254		0.694	0.156		
Retired	9.9	0.509	0.328		0.611	0.187		
Unemployed	57.3	0.596	0.285		0.569	0.189		
Education				0.98			0.11	0.03
Primary or	29.0	0.602	0.255		0.552	0.180		
below								
Junior high	41.2	0.624	0.286		0.629	0.182		
school								
Senior high	18.3	0.625	0.341		0.654	0.194		
school								
College or	11.5	0.627	0.270		0.654	0.182		
above								
Marital status				0.90			0.86	0.76
Divorced	1.5	0.763	0.254		0.554	0.409		
Married	91.6	0.619	0.285		0.619	0.185		
Unmarried	3.1	0.554	0.407		0.564	0.195		
Widow	3.8	0.605	0.189		0.552	0.178		

NYHA				< 0.01			<0.0	1.23
functional							1	
class								
Ι	7.6	0.868	0.089		0.848	0.091		
II	22.9	0.784	0.135		0.688	0.186		
III	53.4	0.608	0.247		0.588	0.171		
IV	16	0.296	0.315		0.484	0.121		
Comorbidities				0.87			0.72	0.22
>2	51.1	0.623	0.304		0.620	0.185		
0-2	48.9	0.614	0.264		0.608	0.188		
Current				0.03			0.64	1.39
smoking								
Yes	17.6	0.722	0.233		0.676	0.165		
NO	82.4	0.596	0.289		0.601	0.189		

*Relative efficiency value of the F-statistics of one-way ANOVA (F-statistics EQ-5D-5L/ Fstatistics SF-6Dv2). NYHA, New York Heart Association; EQ-5D-5L, 5-level EuroQol 5dimension; SF-6Dv2, Short Form Six-Dimension (version 2)

209

210 Comparison

As shown in Fig 1, the scores from the baseline and follow-up measurements were not normally distributed. The distribution of EQ-5D-5L as a starting point and follow-up was

highly left-skewed compared to SF-6Dv2. The most frequently distributed combinations of

SF-6Dv2 and EQ-5D-5L at baseline were 421111 and 11121. The mean utility scores of SF-

6Dv2 and EQ-5D-5L at baseline were 0.61 and 0.62, respectively. The minimum and

216 maximum values generated from the EQ-5D-5L were -0.182 and 1.0, respectively, while the

217	SF-6Dv2 measured -0.277 and 0.962 at its minimum and maximum, respectively. In EQ-5D-
218	5L, a low ceiling effect of 3 (2.3%) was observed. The EQ-VAS measured two (1.5%)
219	participants in optimum health. No instruments produced a floor effect. Over a 3-month
220	follow-up, the mean utility of EQ-5D-5L and SF-6Dv2 was 0.849 (range: -0.391 to 1.0) and
221	0.769 (range: -0.277 to 1.0), respectively (p = 0.000). The floor and ceiling effects of EQ-
222	5D-5L were 2 (1.5%) and 36 (27.5%), respectively, while those of SF-6Dv2 were 2 (1.5%)
223	and 9 (6.9%), respectively. According to the EQ-VAS score, eleven individuals (8.4 %)
224	obtained the best possible health. The 6-month follow-up revealed the following: the mean
225	utility values of EQ-5D-5L and SF-6Dv2 were 0.797 and 0.736 ($p = 0.000$), respectively. The
226	range of values of the two measurements was the same as for the follow-up in March. The
227	floor and ceiling effects of EQ-5D-5L were 1 (0.8%) and 35 (26.7%), respectively, whereas
228	those of SF-6Dv2 were 1 (0.8%) and 8 (6.1%), respectively; and 14 (10.7%) people achieved
229	the highest EQ-VAS scores.
230	

231 Fig 1 Distribution of EO-5D-5L and SF-6Dv2. (A) Distribution of EO-5D-5L at baseline;

(B) Distribution of EQ-5D-5L at 3-month follow-up; (C) Distribution of EQ-5D-5L at 6-232

month follow-up; (D) Distribution of EQ-5D-5L at baseline; (E) Distribution of EQ-5D-5L at 233

3-month follow-up; (F) Distribution of EQ-5D-5L at the 6-month follow-up. EQ-5D-5L: 5-234

level EuroQol 5-dimension. SF-6Dv2: Short-Form Six-Dimensions (Version 2) 235

236

Agreement 237

The overall agreement for the SF-6Dv2 and EQ-5D-5L in utility scores at baseline 238 was moderate (ICC = 0.598). The ICCs at the 3- and 6-month follow-ups indicate good 239 240 agreement when comparing EQ-5D-5L and SF-6Dv2 index scores (S1 Table). The Bland-Altman plots in Fig 2a show an average difference of 0.004, with a wide range of agreement 241

242	from -0. 418 to 0.427 between the ED-5D-5L and SF-6Dv2 index scores. Consequently, the
243	EQ-5D-5L measurement was 35, which was 9% less or 58% larger than the measurement by
244	SF-6Dv2 for 95% of individuals. SF-6Dv2 and EQ-5D-5L had a large discrepancy for lower
245	utility values, with high variation between the two instruments depending on the patient's
246	health status. For better health, EQ-5D-5L produced higher scores, while for poorer health,
247	SF-6Dv2 yielded higher scores. The 3-month follow-up period is shown in Fig 2b. The
248	indicator scores for EQ-5D-5L exceeded those for SF-6Dv2, with an average difference of
249	0.080 in 77.1% of observations. At the 6-month follow-up, as shown in Fig 2c, more than
250	70.2% of the EQ-5D-5L utility scores outperformed the SF-6Dv2 utility scores, with a mean
251	difference of 0.061. The limits of the agreement ranged from -0.208 to 0.330.
252	
253	Fig 2. Bland–Altman plots of the difference in utility values of EQ-5D-5L and SF-6Dv2.
254	(A) At baseline; (B) at the 3-month follow-up; and (C) at the 6-month follow-up. EQ-5D-5L:
255	5-level EuroQol 5-dimension. SF-6Dv2: Short Form Six-Dimension (version 2)
256	
257	A mean difference at the baseline of 0.082 was found between SF-6Dv2 and EQ-5D-
258	5L, which is lower than the recommended MID of 0.041 for SF-6D and 0.074 for EQ-5D. Fig
259	2c shows a mean difference of 0.080 between SF-6Dv2 and EQ-5D-5L, similar to the MID of
260	EQ-5D but greater than the MID of SF-6D. The result of SF-6Dv2 versus EQ-5D-5L was
261	0.061, which was lower than the MID of EQ-5D; however, it was greater than the MID of
262	SF-6D. It is possible that these instruments cannot be interchanged because of their clinical
263	significance.
264	

265 **Convergent validity**

266	The correlations between the SF-6Dv2 and EQ-5D-5L dimensions based on the self-
267	reported health of the patients are presented in Table 3. Except for the dimension of self-care
268	(EQ-5D-5L), most correlations between SF-6Dv2 and EQ-5D-5L at baseline were moderate
269	to weak. Indeed, the highest correlation at baseline and 3-month follow-up between the
270	Anxiety/Depression (EQ-5D-5L) and Mental Health (SF-6Dv2) dimensions was 0.86 and
271	0.85, followed closely by the Role Limitation (SF-6Dv2) and Usual Activities (EQ-5D-5L)
272	dimensions. Stronger correlations were observed at the 6-month follow-up, at which point
273	convergent validity between similar dimensions was evident: Self-Care and Physical
274	Function (0.41) and Self-Care and Role Limitation (0.41). The correlation for each dimension
275	tended to be moderate to strong. Overall, the SF-6Dv2 and EQ-5D-5L utilities were highly
276	correlated at baseline (rho = 0.709), 3-month follow-up (rho = 0.772), and 6-month follow-up
277	(rho = 0.792).

279 Table 3. Spearman correlations among the EQ-5D-5L and SF-6Dv2 domains

			SF-6Dv2	2		
ED-5D-5L	Physical	Role	Social	Pain	Mental	Vitality
	function	limitation	function		health	
At baseline						
Mobility	0.53**	0.52**	0.49**	-0.04	0.25**	0.29**
Self-care	0.19*	0.19*	0.24**	0.10	-0.01	0.12
Usual activities	0.66**	0.71**	0.57**	0.04	0.40**	0.45**
Pain/discomfort	0.45**	0.44**	0.32**	0.22*	0.32**	0.38**
Anxiety/Depressed	0.34**	0.35**	0.25**	0.28**	0.86**	0.45**
At 3-month follow-up						
Mobility	0.58**	0.57**	0.60**	0.16	0.29**	0.30**

me pro	dRxiv preprint doi: https://doi.org. eprint (which was not certified	(10.1101/2023.10.2 by peer review) is It is made available	5.23297528; this the author/funder perpetuity. e under a CC-BY	version posted C r, who has grante 4.0 International	october 25, 20 d medRxiv a license .	023. The copyri license to displ	ght holder for this ay the preprint in
	Self-care	0.32**	0.29**	0.37**	0.37**	0.32**	0.26**
	Usual activities	0.59**	0.60**	0.52**	0.18*	0.31**	0.32**
	Pain/discomfort	0.40**	0.45**	0.26**	0.45**	0.39**	0.46**
	Anxiety/Depressed	0.20*	0.34**	0.20*	0.26**	0.85**	0.46**
	At 6-month follow-up						
	Mobility	0.63**	0.56**	0.49**	0.43**	0.24**	0.50**
	Self-care	0.41**	0.41**	0.49**	0.24**	0.28**	0.36**
	Usual activities	0.68**	0.60**	0.43**	0.28**	0.36**	0.49**
	Pain/discomfort	0.63**	0.58**	0.41**	0.58**	0.42**	0.66**
	Anxiety/Depressed	0.52**	0.51**	0.49**	0.26**	0.59**	0.54**

SD: Standard deviation RE: relative efficiency **p< 0.01 (two-tailed) EQ-5D-5L: 5-level
EuroQol 5-dimension; SF-6Dv2: Short Form Six-Dimension (version 2)

282

283 External validity

SF-6Dv2 and EQ-5D-5L can distinguish between known group validity (Table 2). As 284 measured by the SF-6Dv2 and EQ-5D-5L, participants who were less educated, unmarried, 285 retired, or unemployed, had comorbidities ≤ 2 , and higher NYHA classification tended to 286 287 have lower average utility. Additionally, EQ-5D-5L was considerably more efficient concerning NYHA functional class (RE = 1.23) and current smoking (RE = 1.39). At the 288 same time, SF-6Dv2 performed better concerning sex (RE = 0.01), annual household income 289 (RE = 0.77), employment status (RE = 0.34), education (RE = 0.03), marital status (RE = 290 0.76), and comorbidities (RE = 0.22). 291 292

293 **Discussion**

This study compared the changes over time between the generic health status 294 questionnaires SF-6Dv2 and EQ-5D-5L in patients with HOCM. To the best of our 295 knowledge, this is the first study to compare EQ-5D-5L and SF-6Dv2 instruments in patients 296 with HOCM. A 6-month follow-up allowed us to investigate the sensitivity of the two scales 297 to changes in health status. As reported above, SF-6Dv2 and EQ-5D-5L displayed some 298 parallels with respect to the ability to detect trends in the changes in health utility values. 299 300 However, the absolute amounts of measured utility values were not identical. The two scales had similar average utility values at baseline. However, at the subsequent follow-up visit, 301 302 when the physical function was better than SF-6Dv2, EQ-5D-5L generally showed higher utility in the same patient. These results were consistent with a recent study comparing the 303 two instruments [23,24]. A previous study comparing EQ-5D-5L and SF-6Dv2 in breast 304 305 cancer patients indicated that the utility value of EQ-5D-5L exceeded that of SF-6Dv2, which 306 also agreed with our findings [25]. The percentage change from the baseline in the EQ-5D-5L questionnaire was higher. It is reasonable to assume that EQ-5D-5L is more responsive to 307 change than SF-6Dv2. This might be partly attributed to the different dimensions covered by 308 the two scales and the different utility ranges corresponding to each measure. The ceiling 309 effect of EQ-5D-5L was evident as the NYHA cardiac function class improved after 310 discharge. Our follow-up results showed a higher ceiling effect [26]. The disease's morbidity 311 312 level is thought to be a possible factor influencing the ceiling effect in EO-5D [27]. 313 Numerous previous studies have proven the ceiling effect of EQ-5D-5L [28,29]. These results suggest that an instrument with higher ceiling effects is ineffective in differentiating 314 relatively better health conditions. However, neither EQ-5D-5L nor SF-6Dv2 showed floor 315 effects. As an explanation, most patients received regular treatment on the day of admission 316 accompanied by their family members, which led to improvements in the physical 317 impairment and mental symptoms caused by the disease. In contrast, the SF-6Dv2 involved 318

the period over the previous four weeks and presumably had a recall bias that prevented 319 patients from accurately perceiving physical discomfort and mental impairment within the 320 specified time of the instrument. After the patient was discharged from the hospital at the end 321 of the intervention, due to home care and regular re-examination of chronic diseases, the 322 assessment of the patient's worst self-health status was further reduced. There is no 323 consensus on a methodology for comparing the utility scores of different MAUIs. Owing to 324 325 the lack of a distinct reference standard for basic preference measures assessing health outcomes, we compared the combination of indicators concerned with correlation, 326 327 consistency, convergent validity, and known group validity.

The ICC between the utility scores of the two tools can be observed to be moderate to 328 good, similar to previous findings [30,31]. Nevertheless, the agreement of the instruments 329 330 tended to worsen in patients with a higher NYHA cardiac function classification and poorer 331 disease, that is, patients with lower general health status. Similar findings have been found in other studies, with low consistency between the EQ-5D-5L and SF-6Dv2 in the lower health 332 state and vice versa [32,33]. In addition, the Bland–Altman plots showed that the 95% levels 333 of agreement for both SF-6Dv2 and EQ-5D-5L utilities were higher than the recommended 334 threshold of minimal clinically important difference, implying that clinically significant 335 differences existed between utilities; therefore, the specific tools could not be regarded as 336 interchangeable. Thus, the findings may vary depending on the scale used. 337

Surprisingly, the "pain" domain at baseline was an exception (rho = 0. 22), which is in contrast to the results of other studies that concluded that the correlation was strongest in the area of pain [34,35]. An important consideration for inconsistencies is that pain is not the most prominent symptom of HOCM. As expected, the two questionnaires correlated well in similar domains with improved health status, especially six months after discharge. Hence, when participants possessed better physical function, the construct validity was supported by

a high degree of convergence. In line with this, the phenomenon frequently appears in the
academic literature on the topic of this study. As described below, when describing
dimensions across comparable tools or representing the same concept owing to their names,
there is a risk that it may lead to inaccurate conclusions [36]. When describing dimensions
across instruments as similar or representing the same concept based on their names, there is
a risk that it may lead to incorrect conclusions.

We validated the known group validity of both SF-6Dv2 and EQ-5D-5L. The RE data showed that the SF-6Dv2 had higher discriminatory efficiency than the EQ-5D-5L version for sociodemographic characteristics other than the NYHA classification and whether they are currently smoking. SF-6Dv2 displayed better construct validity than EQ-5D-5L in a similar study [9]. The reason for the greater efficiency level of SF-6Dv2 in recognizing health-related external indicators may be associated with the features of a more detailed system of description, such as physical function and role limitation dimensions [37].

357 However, further research is required to understand these underlying reasons better.

This study fills a data gap in measuring utility values in Chinese patients with HOCM 358 using EQ-5D-5L and SF-6Dv2. Its main advantage is the absence of missing data due to 359 thorough follow-up, which makes the results realistic and reliable. Another advantage of this 360 study is that the EQ-5D-5L and SF-6Dv2 value sets were calculated using the Chinese tariff, 361 which can precisely describe the characteristics of Chinese people. These results can be used 362 363 for future cost-utility and value analyses. The first limitation of this study was the limited sample size and the single-center design. However, it should be considered that hypertrophic 364 obstructive cardiomyopathy is rare and has a relatively low prevalence. Thus, caution should 365 be exercised when making straightforward generalizations and extrapolating the results. 366 Moreover, the questionnaire was completed at baseline using face-to-face interviews and self-367 reports at follow-up, which may have affected the final validity to a certain degree. Finally, 368

369 considering that only a few health-related external indicators were examined, a more
370 comprehensive assessment of the content of the health survey should be conducted in the
371 future.

372

373 Conclusions

The data from Chinese patients with HOCM suggest that the different results obtained for SF-6Dv2 and EQ-5D-5L in the context of CUA were different. Researchers should decide to compare instruments with one another depending on the severity of the problems typically encountered in each area of the disease under study. Notably, considering the distribution advantage, ceiling effect, and discriminant validity, the SF-6Dv2 is appropriate for evaluating patients with HOCM.

380

381 Acknowledgements

The authors sincerely thank all the inpatients who participated in the questionnaire, the assistants who helped us with the questionnaire, and the people who helped us with the mapping: Chongwen Gui (Henan University of Technology), Bowen Xie (Johnson & Johnson), and Jing Liu (Novartis).

386

387 **References**

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC
 guideline for the diagnosis and treatment of patients with hypertrophic

cardiomyopathy[J/OL]. J Am Coll Cardiol. 2020;76:e159-240.

391 DOI:10.1016/j.jacc.2020.08.045.

392	2.	Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten
393		treatment for obstructive hypertrophic cardiomyopathy: A clinical trial. Ann Intern
394		Med. 2019;170:741-8. DOI:10.7326/M18-3016.
395	3.	Bai Y, Zheng JP, Lu F, Zhang XL, Sun CP, Guo WH, et al. Prevalence, incidence and
396		mortality of hypertrophic cardiomyopathy based on a population cohort of 21.9
397		million in China. Sci Rep. 2022;12:18799. DOI:10.1038/s41598-022-20042-9.
398	4.	Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al.
399		Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am
400		Coll Cardiol. 2022;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.
401	5.	Makavos G, Kairis C, Tselegkidi ME, Karamitsos T, Rigopoulos AG, Noutsias M, et
402		al. Hypertrophic cardiomyopathy: An updated review on diagnosis, prognosis, and
403		treatment. Heart Fail Rev. 2019;24:439-59. DOI:10.1007/s10741-019-09775-4.
404	6.	Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP. Assessing health-related quality-
405		of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-
406		5D-based utilities in the Explorer-HCM trial. J Med Econ. 2022;25:51-8.
407		DOI:10.1080/13696998.2021.2011301.
408	7.	Schoonvelde SAC, Wiethoff I, Hiligsmann M, Evers SMAA, Michels M. Quality of
409		life and societal costs in hypertrophic cardiomyopathy: Protocol of the AFFECT-
410		HCM study. Neth Heart J. 2023 [2023-01-26].
411		https://link.springer.com/10.1007/s12471-022-01753-0. DOI:10.1007/s12471-022-
412		01753-0.
413	8.	Murphy RP, Boyce CJ, Dolan P, Wood AM. Valuing the Q in QALYs: Does
414		providing patients' ratings affect population values? Health Psychol. 2020;39:37-45.
415		DOI:10.1037/hea0000806.

416	9.	Abdin E, Chong SA, Seow E, Peh CX, Tan JH, Liu J, et al. A comparison of the
417		reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with
418		schizophrenia and patients with depression in Singapore. Psychiatry Res.
419		2019;274:400-8. DOI:10.1016/j.psychres.2019.02.077.
420	10	. Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L
421		value set for China. Value Health. 2017;20:662-9. DOI:10.1016/j.jval.2016.11.016.
422	11	. Wu J, Xie S, He X, Chen G, Bai G, Feng D, et al. Valuation of SF-6Dv2 health states
423		in China using time trade-off and discrete-choice experiment with a duration
424		dimension. Pharmacoeconomics. 2021;39:521-35. DOI:10.1007/s40273-020-00997-1.
425	12	. Franco KFM, Cabral CMN, Salvador EMES, Miyamoto GC. Comparison between
426		different health state utility instruments in patients with fibromyalgia. Braz J Phys
427		Ther. 2021;25:573-82. DOI:10.1016/j.bjpt.2021.02.006.
428	13	. Stolz M, Albus C, Beutel ME, Deter HC, Fritzsche K, Herrmann-Lingen C, et al.
429		Assessment of health-related quality of life in individuals with depressive symptoms:
430		Validity and responsiveness of the EQ-5D-3L and the SF-6D. Eur J Health Econ.
431		2022 [2022-11-22]. https://link.springer.com/10.1007/s10198-022-01543-w.
432		DOI:10.1007/s10198-022-01543-w.
433	14	. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development
434		and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual
435		Life Res. 2011;20:1727-36. DOI:10.1007/s11136-011-9903-x.
436	15	. Devlin N, Parkin D, Janssen B. Methods for analysing and reporting EQ-5D
437		data[M/OL]. Cham: Springer International Publishing; 2020 [2022-11-16].
438		http://link.springer.com/10.1007/978-3-030-47622-9. DOI:10.1007/978-3-030-47622-
439		9.

- 440 16. Poder TG, Fauteux V, He J, Brazier JE. Consistency Between Three Different Ways
- of Administering the Short Form 6 Dimension version 2. Value Health. 2019;22:837-
- 442 42. DOI:10.1016/j.jval.2018.12.012.
- 17. Brazier JE, Mulhern BJ, Bjorner JB, Gandek B, Rowen D, Alonso J, et al. Developing
- a New Version of the SF-6D Health State Classification System From the SF-36v2:
- 445 SF-6Dv2. Med Care New Version: SF-6Dv2. 2020;58:557-65.
- 446 DOI:10.1097/MLR.00000000001325.
- 18. Walters SJ, Brazier JE. Comparison of the minimally important difference for two
- health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523-32.
- 449 DOI:10.1007/s11136-004-7713-0.
- 450 19. Giavarina D. Understanding bland Altman analysis. Biochem Med. 2015;25:141-51.
 451 DOI:10.11613/BM.2015.015.
- 452 20. Hazra A, Gogtay N. Biostatistics series module 6: Correlation and linear regression.
 453 Indian J Dermatol. 2016;61:593–601. DOI:10.4103/0019-5154.193662.
- 454 21. Heslin M, Chua KC, Trevillion K, Nath S, Howard LM, Byford S. Psychometric
- 455 properties of the five-level EuroQoL-5 dimension and Short Form-6 dimension
- 456 measures of health-related quality of life in a population of pregnant women with
 457 depression. BJPsych Open. 2019;5:e88. DOI:10.1192/bjo.2019.71.
- 458 22. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and
- 459 SF-6D based on hypothetical preferences in a general population. Health Econ.
- 460 2005;14:1169-89. DOI:10.1002/hec.1006.
- 461 23. Ye Z, Sun L, Wang Q. A head-to-head comparison of EQ-5D-5 L and SF-6D in
- 462 Chinese patients with low back pain. Health Qual Life Outcomes. 2019;17:57.
- 463 DOI:10.1186/s12955-019-1137-6.

- 464 24. Bjerk M, Brovold T, Davis JC, Bergland A. Evaluating a falls prevention intervention
- 465 in older home care recipients: A comparison of SF-6D and EQ-5D. Qual Life Res.
- 466 2019;28:3187-95. DOI:10.1007/s11136-019-02258-x.
- 467 25. Li S, Wang M, Liu L, Chen G. Which approach is better in eliciting health state
- 468 utilities from breast cancer patients? Evidence from mainland China. Eur J Cancer
- 469 Care (Engl). 2019;28:e12965. DOI:10.1111/ecc.12965.
- 470 26. Li N, Boonen A, van den Bergh JP, van Kuijk SMJ, Wyers CE, van Oostwaard M, et
- al. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with
- 472 fractures visiting a Fracture Liaison Service. J Med Econ. 2022;25:829-39.
- 473 DOI:10.1080/13696998.2022.2087409.
- 474 27. Bharmal M, Thomas J. Comparing the EQ-5D and the SF-6D descriptive systems to
- 475 assess their ceiling effects in the US general population. Value Health. 2006;9:262-71.
 476 DOI:10.1111/j.1524-4733.2006.00108.x.
- 28. Kangwanrattanakul K. A comparison of measurement properties between UK SF-6D
- and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
- 479 Expert Rev Pharmacoecon Outcomes Res. 2021;21:765-74.
- 480 DOI:10.1080/14737167.2021.1829479.
- 29. Eneqvist T, Nemes S, Kärrholm J, Burström K, Rolfson O. How do EQ-5D-3L and
 EQ-5D-5L compare in a Swedish total hip replacement population? Acta Orthop.
- 483 2020;91:272-8. DOI:10.1080/17453674.2020.1746124.
- 30. Xu RH, Dong D, Luo N, Wong EL, Wu Y, Yu S, et al. Evaluating the psychometric
 properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur J
- 486 Health Econ. 2021;22:547-57. DOI:10.1007/s10198-021-01273-5.
- 487 31. Kularatna S, Senanayake S, Gunawardena N, Graves N. Comparison of the EQ-5D 3L
 488 and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney

489	disease in Sr	i Lanka: A	cross-sectional	survey. BMJ	Open. 2019	:9:e024854.

- 490 DOI:10.1136/bmjopen-2018-024854.
- 491 32. Sun CY, Liu Y, Zhou LR, Wang MS, Zhao XM, Huang WD, et al. Comparison of
- 492 EuroQol-5D-3L and short Form-6D utility scores in family caregivers of colorectal
- 493 cancer patients: A cross-sectional survey in China. Front Public Health.
- 494 2021;9:742332. DOI:10.3389/fpubh.2021.742332.
- 495 33. Kontodimopoulos N, Stamatopoulou E, Gazi S, Moschou D, Krikelis M, Talias MA.
- 496 A comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D utilities of patients with
- 497 musculoskeletal disorders of different severity: A health-related quality of life

498 approach. J Clin Med. 2022;11:4097. DOI:10.3390/jcm11144097.

- 34. Selva-Sevilla C, Ferrara P, Gerónimo-Pardo M. Interchangeability of the EQ-5D and
 the SF-6D, and comparison of their psychometric properties in a spinal postoperative
- 501 Spanish population. Eur J Health Econ. 2020;21:649-62. DOI:10.1007/s10198-020-
- 502 01161-4.
- 50335. Thuppal S, Markwell S, Crabtree T, Hazelrigg S. Comparison between the EQ-5D-3L

and the SF-6D quality of life (QOL) questionnaires in patients with chronic

505obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery

506 (LVRS). Qual Life Res. 2019;28:1885-92. DOI:10.1007/s11136-019-02123-x.

- 36. Goodwin PC, Ratcliffe J, Morris J, Morrissey MC. Using the knee-specific Hughston
 Clinic Questionnaire, EQ-5D and SF-6D following arthroscopic partial meniscectomy
- surgery: A comparison of psychometric properties. Qual Life Res. 2011;20:1437-46.
- 510 DOI:10.1007/s11136-011-9880-0.
- 511 37. Seymour J, McNamee P, Scott A, Tinelli M. Shedding new light onto the ceiling and
 512 floor? A quantile regression approach to compare EQ-5D and SF-6D responses.
- 513 Health Econ. 2010;19:683–96.

514

Supporting information Caption 515

S1 Table. The ICCs of EQ-5D-5L and SF-6Dv2 index scores 516



Figure 1



Figure 2